Search

Your search keyword '"Ennishi, Daisuke"' showing total 166 results

Search Constraints

Start Over You searched for: Author "Ennishi, Daisuke" Remove constraint Author: "Ennishi, Daisuke" Database Unpaywall Remove constraint Database: Unpaywall
166 results on '"Ennishi, Daisuke"'

Search Results

1. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study

3. Collection efficiency and safety of large‐volume leukapheresis for the manufacturing of tisagenlecleucel

4. Clinical significance of gynecological examinations in long-term follow-ups

5. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

6. Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study

7. Evaluating the efficiency and safety of large‐volume leukapheresis using the Spectra Optia continuous mononuclear cell collection protocol for peripheral blood stem cell collection from healthy donors: A retrospective study

8. Negative Prognostic Impact of High-Dose or Long-Term Corticosteroid Use in Patients with Relapsed or Refractory B-Cell Lymphoma Who Received Tisagenlecleucel

9. Efficient granulocyte collection method using high concentrations of medium molecular weight hydroxyethyl starch

11. Hematopoietic stem cell–derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide

12. Long-term outcomes of patients with primary intestinal follicular lymphoma managed with watch-and-wait strategy

13. Supplementary Table S11 and 15 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

14. Supplementary Table S1-3 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

15. Supplementary Table S8-9 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

16. Supplementary Table S12-14 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

17. Supplementary Table S5 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

18. Data from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

19. Supplementary Table S2 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

20. Supplementary Table S3 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

21. Supplementary Methods and Figures from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

22. Supplementary Table S6 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

23. Supplementary Table S10 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

24. Supplementary Figures S1 - S14 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

25. Supplementary Table S1 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

26. Supplementary Table S1-3 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

27. Supplementary Table S3 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

28. Supplementary Table S4 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

29. Supplementary Table S1 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

30. Supplementary Methods and Figures from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

31. Supplementary Table S4 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

32. Supplementary Figures S1 - S14 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

33. Supplementary Table S5 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

34. Data from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

35. Supplementary Table S10 from Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

36. Supplementary Table S2 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

37. Supplementary Table S6 from CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

38. Supplementary Data from An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy

39. Supplementary Data from An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy

40. Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T‐cell therapy

41. Prolonged Cytopenia after CAR-T Cell Therapy Is Associated with BM Niche Disruption and a Sustained Inflammation in the BM

42. Pre-infusion factors predicting early failure after tisagenlecleucel for patients with relapsed/refractory diffuse large B-cell lymphoma: A single institute retrospective analysis

43. Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML

44. Association between early corticosteroid administration and long-term survival in non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation

45. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan

46. Successful neutrophil engraftment supported by granulocyte transfusion in adult allogeneic transplant patients with peri-transplant active infection

47. Impact of the Dose of Post-Transplant Cyclophosphamide and the Start Timing of Tacrolimus in Patients Who Received Allogeneic Stem-Cell Transplantation from Haploidentical Donor

48. Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan

49. Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target

50. Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML

Catalog

Books, media, physical & digital resources